Background Primary cutaneous lymphomas (extranodular non-Hodgkin lymphomas) are rare (incidence 1:100 000). Mycosis fungoides is the most common cutaneous T-cell lymphoma (CTCL) subtype. Treatment options are based on the diagnosis and the stage of the disease. Skin-directed therapies are useful for the initial stages and include topical treatments such as corticosteroids. Betamethasone dipropionate (BD) is a synthetic glucocorticoid with high anti-inflammatory activity, potency and immunosuppressant effects. It is used for topical treatment of CTCL within the following dosage 0.025-0.1% (w/w). In the Portuguese market only one topical cream contains BD at 0.05% (w/w). Objectives To develop a new and stable emulsion containing 0.1% of BD. Methods To accomplish this aim, development, stability, in vitro release and clinical studies of a new topical water-in-oil emulsion containing BD 0.1% w/w were assessed for the topical treatment of CTCL. Results The three batches prepared were physically, chemically and microbiologically stable over a period of 90 days. 40% of BD was released over 6 hours and evaluation of skin lesions showed a favourable clinical effect (less itching, less infiltration, fewer patches and a reduced area of plaque). Conclusions The clinical results show the effective cutaneous improvement of skin barrier conditions during the study.
INTRODUCTION
Primary cutaneous lymphoma refers to cutaneous T-and B-cell lymphomas (CTCLs) that are present in the skin with no evidence of extracutaneous disease at the time of diagnosis and during the following 6 months. Different subtypes of CTCLs, with different prognoses, exist. The most common subtype is mycosis fungoides (MF) (about 60% of all CTCLs). Treatment of CTCL depends on the clinical stage of the disease, 1 2 which is based on skin node, blood and other organ involvement. Diagnosis of MF is based on the presence of atypical lymphocytes permeating the epidermis and present also in the perivascular dermis. Skin-directed therapies are the first-line treatment for early-stage CTCL. 3 General skin care measures of MF include supportive therapies that reduce skin irritation, improve emollience and produce hydration, ameliorating skin inflammatory reactions. Topical corticosteroids are the mainstay of treatment for CTCL, especially class I compounds with acceptable overall response rates. To achieve the highest possible efficiency of symptomatic relief of the pruritus, by reducing spots or even MF plates, and to avoid systemic use of corticosteroids, a new topical compounding containing 0.1% of betamethasone dipropionate (BD) was developed. A large amount of this medicine (500 g) was prepared as the area to be treated is extensive and the treatment has a long duration. In the Portuguese market no topical cream containing a potent corticoid at 0.1% is available; current medicines have 30 g content. Epidemiological studies indicate an incidence of CTCL of about 0.08 per 100 000 inhabitants. Each year, 15-25 new cases are admitted to the dermatology department of Instituto Português de Oncologia Francisco Gentil of Lisbon (IPOLFG), who continue to receive treatment. These data are based on more than 400 patients, including subjects with various subtypes of primary cutaneous lymphoma in several stages.
This topical treatment has been used for patchstage MF for >30 years 4 5 because the risk/benefit ratio has improved, it has a rapid onset of action, low systemic bioavailability and an antiinflammatory effect. For this reason, this hospital and Pharmacy Faculty of Lisbon University developed a new and stable compounding.
The aim of this work was the development, the stability over 90 days, the in vitro release and evaluation of the efficacy (clinical studies) of a new compounding containing BD at 0.1% w/w for skin-directed treatment of patients with CTCL. This formulation is prepared at the hospital pharmacy in 500 g batches.
MATERIALS AND METHODS
BD was purchased by the Pharmaceutical Service of the Portuguese Institute of Oncology (IPO) Francisco Gentil, Lisbon, E.P.E.
Liquid paraffin, white soft paraffin, polysorbate 80 (Tween 80), sorbitan mono-oleate (Span 80), glycerol monostearate 40-55, Cutina GMS and glycerol were obtained from Fagron (Spain). All materials were used according to European Pharmacopoeia specifications.
Emulsion processing
The emulsion was prepared according to the following formula (w/w): surfactants ( polysorbate 80, Tween 80 and sorbitan mono-oleate (Span 80)) 10%, thickening agent (glycerol monostearate 40-55, Cutina GMS) 5%, oily ingredients (liquid and solid paraffin) 48%, humectant (glycerol) 10% and deionised water up to 100%. To prepare the emulsions the oily and aqueous phases were heated separately to 75°C, then the oily phase was added to the water phase and the system mixed (Helipath 130 rpm) with constant agitation until 30°C. The drug, 0.1% of BD, was transferred to a mortar and the emulsion was added at about 30°C following the geometric dilution role.
Three batches of the formulation were produced and packed in aluminium tubes in the IPOLFG Pharmaceutical Service according to Portuguese legal requirements for production of small-scale compoundings in hospital, which reflect good manufacturing practices.
The ingredients were selected according to their safety and efficacy.
Physical and chemical characteristics pH. pH values were determined in triplicate for each formulation using a potentiometric method (Metrohm pH Meter 744, glass electrode).
Rheology. The apparent viscosity and rheological profile were evaluated using a Brookfield rotational viscosimeter (RV DV-II, small sample adapter, spindle 7) at room temperature. Shear rate (1/s) versus shear stress (Pa) plots were obtained by submitting the samples to a shear rate sweep, from 0.6 to 122/s and up and down over a period of 10 min.
Droplet size analysis. The size distribution of the droplets of the three samples of placebo, produced by the three different scales, was measured by light scattering using a Malvern Mastersizer 2000 (Malvern Instruments, Worcestershire, UK) coupled with a Hydro S accessory. To obtain the correct turbidity, about 0.5 g of each sample corresponding to an obscuration of between 5% and 15%, was added to the sample chamber containing 150 mL of water using a stirrer at 700 rpm. Data are expressed as the relative distribution of volume of droplets in the range of size classes (results are displayed as mean±SD; n=3).
BD quantification. High-performance liquid chromatography (HPLC) with ultraviolet detection was used to assay BD in the formulation. A chromatograph Hewlett-Packard series 1100 (detector, pump and software) with a column (LiChroCART 125-4-LiChrospher 100-RP-18 (5 μm)), 15 cm, was used. The analysis was performed at room temperature. Test conditions were: mobile phase-deionised water:acetonitrile (50:50; v/v); solvent-glacial acetic acid:methanol (0.1:100; v/v); ultraviolet detection at 254 nm; flow rate-1.5 mL/min; injection volume-20 μL, injection of each solution three times. Sodium propylparaben (60 mg/100 mL) was used as an internal standard.
Validation of the assay method was carried out according to the guideline, 'Validation of analytical procedures: text and methodology'. 6 7 Physical and microbiological stability. In general, the stability tests performed during development of the formulation were carried out in accordance with the International Council for Harmonisation (ICH), particularly the ICH Q1A (R2), which was adopted by the Committee for Proprietary Medicinal Products (CPMP) (CPMP/ICH/2736/99) in March 2003. 8 9 However, these guidelines have been adapted according to the concept of 'hospital compounding' and for this reason three batches of the emulsion were stored for 3 months at room temperature (25±2°C/60±5% relative humidity), and at a temperature of 5±2°C. Samples were analysed for their macroscopic appearance, pH, apparent viscosity (calculated at 122/s shear rate) and BD chemical stability, assessed by HPLC. Assessment of microbiological stability was carried out according to the European Pharmacopoeia. 10 In vitro release studies. The release profile of BD from the emulsion was measured in finite dose conditions using Franz cells with hydrophilic polysulfone membranes filters 0.45 mm (Tuffryn) from Pall Corporation (Washington, New York, USA) with a diffusion area of 1 cm 2 . Ethanol:water (50:50) was used as a receptor phase to assure perfect sink conditions throughout the experiment. It was constantly stirred with a small magnetic bar (200 rpm) and kept in a thermostat at 32°C±0.5°C throughout the experiments. The emulsion was then applied (0.2 g) evenly onto the surface of the membrane in the donor compartment and immediately sealed by Parafilm (Pechiney Plastic Packaging Co, Chicago, Illinois, USA) to prevent water evaporation. Samples were collected from the receptor fluid at predetermined time points-1, 2, 3, 4, 5 and 6 hours for release studies-and replaced with an equivalent amount (200 mL) of receptor medium. The drug content in the withdrawn samples was analysed by HPLC. A repeated-measures design, with at least six replicated cells for each formulation, was used.
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Clinical studies. BD was prescribed for 91 patients with CTCL with different stages of the disease, as standard clinical practice. The observational study was authorised by the hospital's ethic committee and was conducted in 16 patients with CTCL (MF, stages Ia and Ib) after receiving their written informed consent. Patients with advanced disease were excluded.
Patients with CTCL were evaluated monthly by the physician and skin response was registered in accordance with International Society for Cutaneous Lymphomas/ European Organisation for Research and Treatment of Cancer task force standard criteria 12 (complete response: 100% clearance of skin lesions; partial response ≥50% to <100% reduction from the baseline score; stabilised disease ≥25% increase to <50% clearance of skin disease without new tumours; progressive disease >25% increase of skin disease with new tumours). Affected area, infiltration, pruritus and side effects, such as skin atrophy, telangiectasias and striae, were also evaluated by the physician.
Although pruritus is a subjective symptom its evaluation was based on patients' response to the following question: 'How do you feel about your pruritus'. Possible answers were: worse, the same, less, totally disappeared on a scale 3-2-1-0.
The prescription of BD was 'apply once a day as a thin layer with massage'.
RESULTS

Formulation, physical chemical characteristics and stability
The prepared emulsions had a creamy, matt, white colour with an odourless and homogeneous texture. The pH data showed that the three batches were stable and suitable for skin application ( pH 6.6±0.03). Apparent viscosity was also stable over the study period. The values observed varied from 150 to 222 Pa.s. The emulsion had a shear thinning rheological behaviour.
The amount of BD did not change significantly during the evaluation period for the batches stored at room temperature (25°C±2°C/60%±5% relative humidity). However, the second batch had a reduced BD content, but still within the specifications. This variation might be due to evaporation of the emulsion external phase.
Microbiological studies showed that both formulations were within the recommended specification limits during the time in which they were tested.
Stability results are summarised in table 1. The physical stability of the three batches was assessed upon storage at 25±2°C over a period of 3 months. All batches were stable over this time, with no significant changes ( p≥0.05) in droplet size (table 2) . Nevertheless, batch number 2 did show some increase in droplet size throughout the 90 days of storage, probably due to processing method.
In vitro drug release
The amount of BD released through polysulfone membranes is shown in figure 1 .
After 1 hour, the emulsion released 10% of BD and after 6 hours the percentage of BD released was 40%. A steady state was not achieved.
Preliminary clinical studies
Clinical evaluation of the formulation containing BD at 0.1% w/w was carried out in 16/91 selected patients (stage Ia, Ib) (table 3) . Of the patients, 12 were male (75%), 4 female (25%), 7 were at stage Ia (43.8%) and 9 at stage Ib (56.3%); their median age was 64.5 years (range 36-82 years) during the 3-month study. One of the patients was lost to follow-up.
Fifteen patients completed 3 months of treatment. After 3 months, one had progressive disease (case 8), four patients showed complete response (cases 2, 7, 9, 12), six patients showed partial response (cases 1, 3, 4, 5, 11, 15) and four had their cutaneous disease stabilised (cases 10, 13, 14, 16) . During this period no side effects, such as skin irritation and contact dermatitis, were noticed.
Response was related with infiltration rather than involvement extension.
Even with just one small lesion, and the lowest modified severity-weighted assessment tool (mSwat) score in the first evaluation, patient 14 did not respond, probably because of his folliculotropic subtype.
Symptomatic relief of pruritus was confirmed in all patients, resulting in a good compliance.
DISCUSSION
Many variables are known to influence the physicochemical properties of emulsions. The processing method, the selection of emulsifiers, their combination and concentration has a great impact on the final properties of the formulations. The stability of the emulsions we proposed was investigated by determining the rheological properties over time. Any change in the dispersion of particles, the degree of flocculation or other changes in the structure of the emulsions can lead to changes in the rheological properties of the formulations. During the 3-month Figure 1 Amount of betamethasone dipropionate (BD) released during 6 hours.
period of evaluation, apparent viscosity and pH did not change significantly. However, there were some differences in droplet size and drug assay that might be related to the preparation method. Thus, manual mixing in the mortar was probably unable to assure a good homogeneity of the drug in the emulsion. The amount of corticosteroids recovered from the skin surface after penetration is usually high (about 60-95% of the dose applied) and forms a surface reservoir. 13 14 The ability to develop a reservoir is highly dependent on the vehicle. Vickers 15 in an in vivo study observed that (i) the application of steroids in alcoholic solutions always induced a reservoir (lasting 9.6 days); (ii) the application of hydrophilic creams induced a reservoir in 92% of the volunteers (lasting 7.4 days); (iii) and the application of ointments induced a reservoir in 68% of the volunteers (lasting 4.6 days). Although 40% of the drug was released from the vehicle, the clinical data so far obtained in this work can be explained by the reservoir theory. There is also a possible interaction between the solvents (oily phase and bulk water) of the emulsions and the membrane, reducing the diffusion of the drug. It is also possible, that water in the formulation had evaporated, leading to changes in the thermodynamic activity of the drug.
The selected excipients were chosen according to their safety and efficacy. The polysorbates are used as general purpose, hydrophilic, non-ionic surfactants in a variety of cosmetic products. Some of the polysorbates are also approved by the Food and Drug Administration for use in various pharmaceuticals and food products. Polysorbate 80 was shown to be non-mutagenic in the Ames and micronucleus tests. The polysorbates have been shown in numerous studies to be non-carcinogenic. The Cosmetic Ingredient Review concluded that polysorbates were safe as cosmetic ingredients. 16 Glycerol monostearate 40-55 was used as co-emulsifying agent. According to the FDA, many of the monoglyceryl monoesters are direct food substances, generally recognised as safe and they are considered safe for use and at the concentration described in this emulsion.
The skin barrier repair capacity was influenced by topical application of exogenous lipids. 17 In this study we used a water-in-oil emulsion for enhanced skin moisturisation and emollience. The lipidic components included in the formulation developed were chosen considering the composition of the oily phase, paraffin, which is an occlusive ingredient. Glycerin is a natural component of all animal and vegetable fats and oils. It is used for its humectant properties, preventing the premature loss of moisture from the emulsion.
No preservative was added to this formulation. In pharmaceutical pratice, semisolid formulations are the preferred vehicles for dermatological treatment because they remain in situ and deliver the drug over an extended time. 
What this paper adds?
What is already known on this subject? ▸ Skin-directed therapies are the first-line treatment for early-stage cutaneous T-cell lymphoma (CTCL). ▸ General skin care measures of mycosis fungoides (MF) include supportive therapies that reduce skin irritation, improve emollience and produce hydration, ameliorating skin inflammatory reactions. ▸ Topical corticosteroids are the mainstay of treatment for CTCL, especially class I.
What this study adds? ▸ In order to have the highest possible efficiency of symptomatic relief of the pruritus, in reducing spots or even mycosis fungoides plates, and to avoid corticosteroids systemic use, a new topical compounding containing 0.1% of betamethasone dipropionate (BD), class II-III, was developed. ▸ This compounding was prepared at the hospital pharmacy in 500 g batches. ▸ The compounding was physically, chemically and microbiologically stable over a period of 90 days. The amount of BD released was 40% and evaluation of skin lesions showed a favourable clinical effect.
Moreover, the recommendations presented and good-quality supporting data and guidelines suggest that skin-directed therapies are the most appropriate choice for early-stage MF.
Corticosteroids are frequently used in CTCL. Their multiple effects include induction of apoptosis, impact on lymphocyte adhesion to endothelium, among others. A favourable response was seen in the early stages of CTCL. The clinical results account for the effective cutaneous improvement of skin barrier conditions during the period of this study.
CONCLUSIONS
The results obtained showed that the three batches prepared were physically, chemically and microbiologically stable over a period of 90 days. The amount of BD released was 40% over 6 hours and the evaluation of skin lesions showed a favourable clinical effect (reduction of itching, infiltration, patches and area of plaques).
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